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Abstract
Apoptosis is an important mechanism by which virus-infected cells are eliminated from the host. Accordingly, many viruses
have evolved strategies to prevent or delay apoptosis in order to provide a window of opportunity in which virus
replication, assembly and egress can take place. Interfering with apoptosis may also be important for establishment and/or
maintenance of persistent infections. Whereas large DNA viruses have the luxury of encoding accessory proteins whose
primary function is to undermine programmed cell death pathways, it is generally thought that most RNA viruses do not
encode these types of proteins. Here we report that the multifunctional capsid protein of Rubella virus is a potent inhibitor
of apoptosis. The main mechanism of action was specific for Bax as capsid bound Bax and prevented Bax-induced apoptosis
but did not bind Bak nor inhibit Bak-induced apoptosis. Intriguingly, interaction with capsid protein resulted in activation of
Bax in the absence of apoptotic stimuli, however, release of cytochrome c from mitochondria and concomitant activation of
caspase 3 did not occur. Accordingly, we propose that binding of capsid to Bax induces the formation of hetero-oligomers
that are incompetent for pore formation. Importantly, data from reverse genetic studies are consistent with a scenario in
which the anti-apoptotic activity of capsid protein is important for virus replication. If so, this would be among the first
demonstrations showing that blocking apoptosis is important for replication of an RNA virus. Finally, it is tempting to
speculate that other slowly replicating RNA viruses employ similar mechanisms to avoid killing infected cells.
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Introduction
Rubella virus (RV) is an enveloped positive strand RNA virus in
the family Togaviridae and is the sole member of the genus
Rubivirus (reviewed in [1]). Humans are the only natural host for
RV and in most cases the virus causes a systemic infection the
symptoms of which include maculopapular rash, lymphadenopa-
thy, low-grade fever, conjunctivitis and sore throat. However, RV
infections can be complicated by the appearance of acute or
chronic arthralgia, arthritis, thrombocytopenia and encephalopa-
thy. In utero infection during the first trimester of pregnancy often
results in a characteristic series of birth defects known as
congenital Rubella syndrome. Worldwide, RV is thought to cause
more birth defects that any other infectious agent yet, very little is
known about molecular aspects of viral pathogenesis. A number of
studies suggest that viral persistence may underlie some of the most
serious aspects of infection including congenital Rubella syndrome
and arthritis [2,3,4,5,6].
Among the togavirus family, RV is unique in that its replication is
associated with mitochondria. The link between RV infection and
thisorganellefirstbecameapparentwhenanalysisofpurified virions
revealed that cardiolipin, a phospholipid that is only found in
mitochondria, is a significant component of the RV envelope [7].
Subsequently, it was discovered that RV infected cells exhibit
striking mitochondrial defects. Virus infection induces clustering of
mitochondria in the perinuclear region as well as formation of
electron-dense plaques between apposing mitochondrial cisternae:
structures that have been termed confronting membranes [8,9].
The function of these structures is not known but expression of
capsid protein in the absence of other RV proteins is sufficient to
induce their formation [10]. A large pool of the capsid protein
localizes to the surface of mitochondria [11] and the inter-
mitochondrial plaques [12] but given that assembly of RV virions
occurs primarily on Golgi membranes, the targeting of the capsid to
this organelle likely reflects a nonstructural function of this protein.
The studies described above underscore the close link between
the capsid protein and mitochondria in RV biology and form the
basis for our central hypothesis; that association of the RV capsid
protein with mitochondria is important for virus replication. All
viruses must contend with host cell anti-viral mechanisms and
large DNA viruses have the luxury of harboring in many cases,
multiple genes devoted to thwarting host cell defenses (reviewed in
[13]). In contrast, simple RNA viruses express a very limited
number of proteins, most of which are directly involved in
replication and virus assembly. Accordingly, it is beneficial if not
essential that these viral proteins have multiple functions.
It is well documented that togavirus infection often results in
apoptotic death of mammalian cells (reviewed in [14,15]) and to
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members of this virus family inhibit programmed cell death
pathways. With the exception of RV, togavirus replication and
virus egress from vertebrate cells occurs within 4–6 hours followed
by extensive death by apoptosis within 24 hours. Accordingly, for
most togaviruses, preventing apoptosis is likely not required in
order for efficient replication to occur. In contrast, the replication
cycle for RV is unusually slow; the eclipse period is at least
12 hours and viral titers peak virion secretion occurs between 48–
72 (reviewed in [16]). RV-induced apoptosis in mammalian cells
has been reported but generally, extensive cytopathic effect is not a
hallmark of RV infection. When apoptosis does occur, it is not
until 5–7 days post-infection that maximum levels are reached [17]
and this is well past the peak virus production phase. In the present
study, we report that the capsid protein blocks apoptosis in RV
infected cells most likely to allow sufficient time for virus
replication. This process occurs at the level of mitochondria
through a Bax-dependent pathway.
Results
Cells infected with RV are resistant to apoptosis
We reasoned that in order for RV replication and virion
secretion to increase through 48 hours and beyond, programmed
cell death must be inhibited during this period. Accordingly, we
compared the levels of apoptosis in RV and mock-infected A549
cells by indirect immunofluorescence using an antibody specific
for activated caspase 3. Interestingly, less than 5% of infected
cells exhibited signs of apoptosis 48 hours post-infection
(Figure 1A and B). Moreover, when challenged with the kinase
inhibitor staurosporine, a potent inducer of apoptosis [18], RV
infected cells were significantly more resistant to apoptosis than
mock infected cells. Specifically, the percentage of caspase 3-
positive cells was almost three fold lower in the infected samples.
This was not due to detachment of infected cells as data in
Figure 1C show that treatment with staurosporine did not cause
significant loss of infected cells. Finally, Figure 1D shows that
even after 72 hours, RV infection does not significantly affect the
percentage of viable A549 cells. Together, these data indicate
that RV-infected A549 cells are resistant to programmed cell
death.
Expression of capsid protein inhibits apoptosis
Next, we sought to determine which viral protein(s) was
primarily responsible for protecting infected cells against apoptosis.
Previous studies have indicated that expression of the nonstruc-
tural proteins p150 and p90 are cytotoxic [19,20] and therefore,
we focused our attention on the virus structural proteins. Plasmids
encoding glycoproteins E2 and E1 or capsid, were transiently
tranfected into A549 cells and at 40 hours post-transfection, cells
were induced to undergo apoptosis by treatment with anti-Fas.
Samples were processed for indirect immunofluorescence
(Figure 2A) and the numbers of active caspase 3-positive
transfectants were determined. Data in Figure 2B show that the
levels of apoptosis were similar in cells expressing the viral
glycoproteins E2 and E1 and the negative control protein eGFP.
In contrast, expression of the RV capsid protein was just as
protective against anti-Fas as the well-characterized anti-apoptotic
protein Bcl-XL [21]. Compared to eGFP or E2E1 transfectants
that were treated with anti-Fas, the percentage of apoptotic cells
among capsid transfectants was three fold lower (Figure 2B).
We also examined whether RV infection and/or capsid
expression protects Vero cells from apoptosis. This cell line is
used extensively to study RV replication and similar to what was
observed with A549, infection of Vero cells with RV, or transient
expression of capsid protein conferred protection from stauros-
porine-induced apoptosis (Figure S1A, B, arrowheads). Because
Vero cells do not respond to anti-Fas treatment, it was not possible
to determine the effect of capsid expression on death receptor
pathways. These data appear to be at odds with a previous study
which reported that the RV capsid was pro-apoptotic in RK-13
cells [22]; a cell line that is exquisitely sensitive to RV-induced
apoptosis [23]. Accordingly, we assayed intrinsic and extrinsic
apoptotic pathways by staurosporine and anti-Fas treatment of
RK-13 cells at 48 and 72 hours post-transfection. In both cases,
expression of the capsid protein conferred resistance to apoptosis
similar to Bcl-XL (Figure S2). Together, these data indicate that
the RV capsid is an anti-apoptotic protein that protects cells from
multiple apoptotic stimuli.
Capsid protein blocks activation of the mitochondrial
apoptotic pathway
We next endeavored to identify what step in apoptotic signaling
was blocked by capsid protein. For these experiments, lentiviral
transduction was used to create A549 cells that stably express
capsid protein under the control of a doxycycline-regulated
promoter. Results from indirect immunofluorescence showed that
less than 50% of the polyclonal population of transduced cells
expressed RV capsid following doxycyline treatment (Figure 3A).
Similar to results shown in Figure 2, induction of capsid expression
protected the stably transduced A549 cells against staurosporine-
and Fas-mediated activation of caspase 3 (Figure S3). To further
confirm that apoptotic stimuli do not activate caspases in these
cells, we measured the appearance of the downstream caspase 3
substrate, cleaved Poly(ADP-ribose) polymerase (PARP). Figure 3B
shows that expression of capsid protein results in decreased anti-
Fas-induced cleavage of PARP compared to luciferase-expressing
cells. These data indicate that capsid protects A549 cells from
staurosporine and anti-Fas treatment by blocking caspase
activation.
We next determined where upstream of caspase 3 activation,
that capsid protein acted. Both staurosporine- and anti-Fas- can
trigger apoptosis through the mitochondrial pathway, so we tested
the ability of capsid protein to block depolarization of mitochon-
drial membranes in response to apoptotic stimuli. Doxycycline-
treated A549 cells expressing capsid protein or luciferase were
Author Summary
Among the variety of defense systems employed by
mammalian cells to combat virus infection, apoptosis or
programmed cell death is the most drastic response. Some
large DNA viruses encode proteins whose sole function is
to block apoptosis. Conversely, very little is known about
whether RNA viruses encode analogous proteins. In many
cases, RNA viruses are able to replicate before cell death
occurs, which may be one reason why so little thought has
been given to this topic. However, a number of RNA
viruses, some of which are important human pathogens,
have slow replication cycles and it stands to reason that
they must block apoptosis during this time period. Here
we show that the multifunctional capsid protein of Rubella
virus is a potent inhibitor of apoptosis. Data from reverse
genetic experiments suggest that the anti-apoptotic
function of a virus-encoded protein is important for
replication of an RNA virus. We anticipate that other
slowly replicating RNA viruses may employ similar
mechanisms and, as such, these studies have implications
for development of novel anti-virals and vaccines.
Anti-Apoptotic Viral Capsid Protein
PLoS Pathogens | www.plospathogens.org 2 February 2011 | Volume 7 | Issue 2 | e1001291Figure 1. Caspase 3 activation is blocked in RV infected cells. A. A549 were infected with RV (MOI=1) for 42 hours after which they were
treated with staurosporine (ST) for 6 hours. Samples were then processed for indirect immunofluorescence using rabbit anti-caspase 3 and mouse
anti-capsid. Primary antibodies were detected with donkey anti-rabbit Alexa488 and chicken anti-mouse Alexa594. Nuclei were counter stained with
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the membrane potential sensitive dye TMRM. Samples were
analyzed by FACS, after which the relative specific cell death
levels for each sample were calculated (Figure 3C). Data in
Figure 3D show that compared to luciferase, expression of capsid
protein reduced the relative specific death induced through
intrinsic (staurosporine) or death receptor-dependent pathways
(Fas) by 20–35%. However, because less than 50% of the
lentivirus-transduced cells express detectable levels of capsid
protein, these numbers likely underestimate the true level of
protection afforded by stable expression of the RV capsid protein.
Bax and Bak are two key apoptotic molecules that form
oligomers on mitochondria [24,25,26] and apoptosis occurs when
the mitochondrial outer membrane is permeabilized by these
pore-forming molecules [27]. Accordingly, we next focused our
efforts on these Bcl-2 family members starting with Bax. Normally,
Bax is an inactive monomer found in the cytosol or loosely bound
to the mitochondrial outer membrane of healthy cells [28,29]. In
response to apoptotic stimuli, Bax activation is characterized by a
multi-step process whereby it undergoes a conformational change
[30,31], integrates into the mitochondrial membrane [28,32]
where it forms higher order oligomers [33]. It is the large Bax
oligomers that are linked to the formation of membrane pores that
facilitate release of mitochondrial cytochrome c and downstream
caspase activation [33,34]. Of these multiple steps, Bax confor-
mational change can be detected by immunoreactivity with a
conformation-specific antibody, 6A7 [35,36]. We observed that
RV infection induces Bax conformational change, however
cytochrome c remained associated with mitochondria (Figure 4A,
arrows). Moreover, Bax conformational change as detected by
6A7 staining was evident in the majority (76%) of cells expressing
capsid protein (Figure 4B arrows). In contrast, among cells
expressing the viral glycoproteins E2 and E1, only 6% contained
activated Bax. Despite initial stimulation of Bax, similar to infected
cells, no loss of cytochrome c from mitochondria was observed in
capsid-expressing cells. Because capsid protein stimulates Bax in a
manner that does not produce functional pores that mediate efflux
of cytochrome c, we initially thought that capsid protein blocks
oligomerization of Bax. However, data in Figure 5A indicate that
this is not the case. Rather, our results suggest that capsid protein
and Bax form mixed large hetero-oligomers even in the absence of
apoptotic stimuli. Indeed, reciprocal co-immunoprecipitation
experiments confirmed that capsid forms a stable complex with
Bax (Figure 5B). Staurosporine treatment enhanced the formation
of the capsid:Bax hetero-oligomers but evidently did not facilitate
the assembly of functional Bax pores as the cells were not
apoptotic. Interestingly, we found no evidence that capsid protein
binds to Bak (Figure 5C) suggesting the interaction of this viral
protein with Bcl-2 family proteins is highly specific. Together,
these data suggest that capsid protein and Bax form mixed
oligomers that do not function as pores.
Capsid protein protects against Bax- but not Bak-induced
apoptosis
Since capsid protein forms a complex with Bax, we next tested
whether its expression could inhibit Bax-mediated apoptosis.
Over-expression of either Bax or Bak induces cell death in the
absence of other apoptotic stimuli [37]. A549 cells were co-
transfected with plasmids encoding GFP-Bax and capsid, Bcl-XL
(positive control) or vector alone (negative control) and at 24 hour
post-transfection, samples were stained with the membrane-
potential specific dye TMRM and then subjected to flow
cytometric analyses (Figure 6A). As a second control, we
transfected cells with a plasmid encoding a capsid deletion
construct (CapNT) that is not targeted to mitochondria (see
below). Loss of TMRM staining as a result of depolarization of
mitochondrial membranes was used as the measure of apoptotic
cell death. Quantitation of the data (Figure 6C) revealed that
expression of capsid protein reduced the level of Bax-induced cell
death by more than 60% compared to CapNT or vector alone.
Similar results were observed for cells expressing Bcl-XL, a protein
which has previously been shown to block the effects of Bax over-
expression [38]. Data in Figure S4 show that capsid expression
also protects primary human embryonic fibroblast (HEL-18) cells
[17] from Bax-mediated apoptosis. The anti-apoptotic activity of
capsid protein was specific to Bax as evidenced the fact that it did
not attenuate Bak-mediated apoptosis (Figure 6B, C).
To further understand how capsid functions to block apoptosis,
we determined whether expression of this viral protein inhibits
Bax-induced release of cytochrome c. A549 cells were co-
transfected with plasmids encoding GFP-Bax and capsid or empty
vector. Localization of cytochrome c was monitored by fluores-
cence microscopy at 24 hours post-transfection. As expected, in
cells expressing GFP-Bax and vector alone, there was marked loss
of cytochrome c from mitochondria (Figure 7A, asterisks). In
contrast, in cells that expressed both capsid protein and GFP-Bax,
cytochrome c remained associated with this organelle (Figure 7A,
arrows). However, consistent with data shown in Figures 5 and 6,
capsid did not block GFP-Bak-induced loss of cytochrome c from
mitochondria (Figure 7B arrows).
Capsid:Bax interactions form the basis for the anti-
apoptotic activity of capsid
Based on the assumption that association of capsid protein with
mitochondria is critical for its anti-apoptotic function, we next
mapped the region of capsid protein that is required for targeting
to this organelle. Analyses of the RV capsid protein sequence with
web-based algorithms such as PSORT II Prediction (http://psort.
nibb.ac.jp/form2.html) indicated that conventional mitochondrial
targeting signals are absent. We therefore constructed a series of
capsid deletion mutants whose localizations were determined by
expression in A549 cells (Figure 8A). From the indirect
immunofluorescence data shown in Figure 8B, it can be seen that
the 23 amino acid residue E2 signal peptide which forms the
hydrophobic carboxyl-terminus of capsid protein, is required for
association with mitochondria. Moreover, the observation that a
pool of CapCT overlaps with cytochrome c indicates that the
carboxyl-terminal region of capsid protein contains information
that is sufficient for targeting to mitochondria. Intriguingly,
expression of the CapCT construct caused extreme compaction
of the mitochondrial network to the perinuclear region, much
more so than in cells expressing full-length capsid protein.
DAPI. Scale bar =20 mm. B. The percentages of cells among mock and RV infected cells treated with ST expressing active caspase 3 were determined
and plotted. Student’s t-Test was performed to determine statistical significance. p=#0.001. Percentages were determined from three independent
experiments in which at least 100 cells for each experiment were scored. C. To demonstrate that ST treatment did not result in selective loss of
infected cells, the percentages of RV infected cells were determined in control (RV) and ST-treated (RV + ST) samples. D. The percentage of viable cells
in mock and RV infected samples were determined by Trypan blue dye exclusion at the indicated time points. Error bars indicate standard deviations
calculated from three independent experiments.
doi:10.1371/journal.ppat.1001291.g001
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PLoS Pathogens | www.plospathogens.org 4 February 2011 | Volume 7 | Issue 2 | e1001291Figure 2. Expression of RV capsid protein blocks activation of caspase 3. A. A549 cells were transiently transfected with plasmids encoding
eGFP, RV glycoproteins E2 and E1, capsid protein or the anti-apoptotic protein Bcl-XL. At forty hours post-transfection, cells were treated with anti-Fas
for 6 hours after which time they were processed for immunofluorescence using rabbit anti-caspase 3 and mouse antibodies to E1, capsid or Bcl-XL.
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mitochondria correlated with its ability to block apoptosis.
Transfected cells expressing the various capsid constructs were
challenged with staurosporine or anti-Fas, and then apoptosis
induction was assessed using the activated caspase 3 assay. The
amino-terminal capsid construct (CapNT) neither associates with
mitochondria nor protects against apoptosis (Figures 8, 9).
Conversely, CapCT, a pool of which is targeted to mitochondria,
protects as well as full-length capsid protein against staurosporine
and anti-Fas challenge. CapDRSP, which lacks the hydrophobic
E2 signal peptide and a membrane proximal arginine-rich (R)
motif, is not targeted to mitochondria and does not block
staurosporine or anti-Fas-mediated induced activation of caspase
3. Interestingly, although CapDSP does not localize to mitochon-
dria, it did confer resistance to both Fas- and staurosporine-
induced apoptosis (Figure 9). This observation suggests that the
membrane-proximal R motif is important for the anti-apoptotic
function of capsid. Table 1 summarizes the localization and anti-
apoptotic properties of the capsid deletion mutants.
To investigate if the arginine residues in the membrane-
proximal R motif were important for the anti-apoptitic function of
capsid protein, we created a point mutant (CapCR5A) in which
five arginines in this motif were changed to alanine residues
(Figure 10A). This capsid mutant was targeted to mitochondria
where it activated Bax and stimulated cytochrome c release in the
absence of apoptotic stimuli (Figure 10B and C asterisks);
indicating that the arginine residues within the R domain are
critical for the anti-apoptotic activity of capsid protein. Moreover,
it would appear that mutation of these arginine residues unmasks
an intrinsic pro-apoptotic activity of capsid protein, which may
explain why it alone can stimulate Bax conformational change and
membrane insertion. Next, we compared the Bax-binding ability
of the CR5A mutant relative to wild type capsid and capsid
deletion constructs. The observation that more CapDSP is
recovered in anti-Bax coimmunoprecipitations than CapDRSP
(Figure 11A) suggests that the R domain is important for
interaction with Bax. However, ablation of the arginine residues
in the R domain did not affect binding to Bax indicating that the
arginine residues per se in this motif are not essential for interaction
with Bax (Figure 11A). Binding between Bax and CapCT or
CapNT was not detected in our assays (Figure 11B). Indirect
immunofluorescence analyses revealed that unlike wild type capsid
and CapCR5A, neither CapNT, CapCT, CapDSP nor CapDRSP
induced the 6A7-specific conformation change in Bax (data not
shown). Together, these results suggest that capsid protein employs
a multi-step mechanism to block apoptosis. Specifically, binding to
Bax through the R domain and/or the carboxyl terminus
stimulates a conformational change in Bax; but pore formation
and/or functionality is blocked by the arginines in the R motif of
capsid protein.
Recombinant viruses with mutations in the R domain are
less resistant to apoptosis and are replication defective
We introduced the CR5A mutations into the capsid gene of a
RV infectious clone in order to determine if the membrane-
proximal arginine-rich (R) domain in capsid protein is required for
blocking apoptosis during infection. Our hypothesis was that early
onset apoptosis would result in decreased replication and virus
particle production. A549 cells were infected with wild type or
CR5A strains of RV and virus replication and apoptosis induction
were analyzed. Data in Figure 12A show that cells infected with
CR5A virus were significantly more susceptible to Fas-dependent
apoptosis. Moreover, in non-treated (control) samples, the level of
virus-induced apoptosis was four fold higher in cells infected with
the CR5A mutant. Similar results were obtained with infected
Vero cells (data not shown). Next, we compared the levels of RV
proteins in CR5A and wild type (WT) RV infected cells as a
function of time. Figure 12B shows that in cells that were infected
with WT RV, the level of virus nonstructural (p150) and structural
proteins (capsid) peaked at 72 hours. In contrast to p150 levels
which were only moderately lower, steady state levels of capsid
protein were dramatically lower in CR5A infected cells at all time
points. To control for the possibility that CR5A capsid was
unstable in the infected cells, we also determined the relative levels
of another structural protein, E1. Similar to capsid protein levels in
CR5A infected cells, levels of E1 were much lower than in WT
virus infected cells; suggesting a defect in synthesis of structural
proteins in CR5A infected cells. Consistent with this theory, data
in Figure 12C show that secretion of CR5A virions is severly
impaired. This was not because the CR5A capsid is misfolded as
data in Figure S5 show that this mutant capsid protein functions as
well as wild type capsid in driving assembly and secretion of
Rubella virus-like particles.
Nonstructural proteins are translated directly from the 40S
genomic RNA whereas capsid and other structural proteins are
made from a subgenomic RNA. Accordingly, it is possible that
virus transcription and replication are impaired in the CR5A
mutant. Quantitative RT-PCR with p90 specific primers was used
to determine the relative levels of genomic RNA in the WT and
CR5A infected samples (Figure 12D). From these data, it can be
seen that replication of viral RNA was severely affected in CR5A
infected cells. This was not due to decreased infection efficiency
because at six hours post-infection, there was on average .50%
more genomic RNA in CR5A infected cells (Table 2). Moreover,
as demonstrated by plaque assays, cells infected with CR5A virus
did release infectious virus (Figure 12E). Interestingly, the CR5A
plaques were larger and had a spotty appearance compared to
wild type virus-produced plaques which were smaller and clearer.
Although data in Figure S5 indicate that Cap5RA is not
misfolded, without additional investigation, we could not com-
pletely rule out the possibility that the replication defects
associated with the CR5A strain virus were due to other inherent
defects of the mutant capsid protein. Therefore, we attempted to
artificially block apoptosis by over-expression of Bcl-XL or adding
the caspase inhibitor Z-VAD-FMK to CR5A infected cells. Over-
expression of Bcl-XL did not rescue the CR5A replication but this
result was non-informative as further investigation revealed that
this anti-apoptotic protein was unable to protect mitochondria
from the effects of CapC5RA in transfected cells (data not shown).
In contrast, addition of Z-VAD-FMK did have a modest effect on
production of viral proteins in CR5A infected cells (Figure 13A).
The effect was most pronounced at 72 hrs post-infection where
levels of p150 and capsid were considerably higher in Z-VAD-
FMK treated cells. In contrast, blocking caspase activity in cells
Primary antibodies were detected with donkey anti-rabbit Alexa488 and chicken anti-mouse Alexa594. For samples expressing eGFP, the rabbit anti-
caspase 3 was detected with donkey anti-rabbit conjugated to Texas Red. Nuclei were counter stained with DAPI. Scale bar =10 mm. B. The
percentages of transfected cells expressing active caspase 3 (double positive) were determined and plotted. Error bars indicate standard deviations
calculated from three independent experiments in which at least 100 cells for each experiment were scored. One-way ANOVA was used to determine
statistical significance. p=#0.001.
doi:10.1371/journal.ppat.1001291.g002
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PLoS Pathogens | www.plospathogens.org 7 February 2011 | Volume 7 | Issue 2 | e1001291Figure 3. Expression of capsid in stably transduced A549 cells protects against staurosporine- and Fas-induced depolarization of
mitochondria and PARP cleavage. A. A549 cells were stably transduced with a lentivirus encoding RV capsid. Following induction with
doxycycline (Dox), approximately ,40% of cells were found to express capsid protein as detected by indirect immunofluorescence with a mouse
monoclonal antibody and chicken anti-mouse Alexa594. Nuclei were counter stained with DAPI. Scale bar =10 mm. B. Cells expressing capsid (Cap) or
luciferase (Luc) were treated with anti-Fas for 0, 2 and 6 after which levels of cleaved PARP (c-PARP) were determined by immunoblotting. Monitoring
GAPDH levels was done to illustrate comparable loading. C. Capsid protein or luciferase expression was induced with doxycycline for 48 hours and
then cells were treated with staurosporine (ST) or anti-Fas antibody for 6 hours to induce apoptosis. Samples were then stained with TMRM for 30
minutes and then subjected to flow cytometric analyses. The relative level of specific cell death in each sample was calculated and plotted (D). Error
bars indicate standard deviations. Student’s t-Test was performed to determine statistical significance *p#0.01 **p#0.005.
doi:10.1371/journal.ppat.1001291.g003
Figure 4. RV infection activates Bax. A. A549 cells were infected with RV (MOI=1) and then processed for indirect immunofluorescence after
48 hours. Samples were stained with goat anti-RV, rabbit anti-cytochrome c and a mouse monoclonal (6A7) that recognizes activated Bax. Primary
antibodies were detected with chicken anti-goat Alexa488, donkey anti-rabbit Alexa637, and chicken anti-mouse Alexa594. B. A549 cells were
transiently transfected with plasmids encoding RV capsid, glycoproteins E2 and E1 or vector alone. After 48 hours, samples were processed for
indirect immunofluorescence as described in A. Images shown are representative of three independent experiments in which at least 100 infected or
transfected cells were examined. Scale bar =10 mm.
doi:10.1371/journal.ppat.1001291.g004
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steady state levels of viral proteins. Finally, it can be seen from the
data in Figure 13B that Z-VAD-FMK treatment had a modest
effect on production of CR5A virus. Compared to CR5A-infected
Vero cells treated with DMSO alone, addition of Z-VAD-FMK
resulted in a modest increase in viral titers as evidenced by
increased clearing of RK-13 monolayers. Together, these data are
consistent with our hypothesis that the anti-apoptotic function of
capsid is important for virus replication.
Discussion
Apoptosis is a common defense mechanism used by host cells to
limit the spread of viral infections and consequently, a number of
viruses have developed mechanisms to disrupt programmed cell
death pathways. With few exceptions, all known viral apoptosis
inhibitors are accessory proteins that are encoded by DNA viruses
and therefore, a great deal of effort has focused on these proteins
(reviewed in [39]). Ironically, even though RNA viruses cause the
vast majority of viral diseases in humans, comparatively little is
known about if or how these types of viruses interfere with
apoptotic signaling. Among the exceptions are picornaviruses, a
number of which encode ‘‘security’’ proteins (leader protein and
2BC) that can block apoptosis [40,41]. The mechanisms by which
these proteins block apoptosis are not known and interestingly,
caspase activation can still occur normally. These proteins may not
actually prevent cell death per se, but rather, shift the balance
toward necrotic cell death as opposed to apoptosis.
Hepatitis C virus (HCV) is known to modulate apoptotic
signaling but unlike picornaviruses, this virus is not cytolytic and
readily establishes persistent infections in vivo. HCV encodes a
number of proteins that reportedly exhibit anti-apoptotic activity.
For example, the nonstructural proteins NS2 and NS5A interfere
with programmed cell death by different mechanisms [42,43]. The
functions of HCV structural proteins in apoptotic signaling events
are less clear; in particular, the core/capsid protein. The majority
of data suggest that this protein acts to induce apoptosis although a
number of published studies suggest otherwise (reviewed in [44]).
Similarly, with one exception [45], expression of HCV E2
glycoprotein reportedly acts in a pro-apoptotic manner
[46,47,48]. By and large, these studies involved plasmid-based
expression of individual HCV proteins and indeed the data
provide much to ponder with respect how this virus interfaces with
apoptotic pathways. However, it is still not clear how individual
HCV proteins or those of any other RNA virus affect cell death
during infection.
Multiple laboratories have reported that RV infection induces
programmed cell death in a variety of cultured cell lines
[17,19,23,49,50] but it is worth noting that in virtually all cases,
maximum synthesis of viral macromolecules and release of virions
occur well before extensive apoptosis is observed. For example, in
Vero cells, robust expression of structural proteins is first detected
at 16 hours post-infection and secretion of infectious virions peaks
32 hours later [51]. Conversely, late apoptotic events such as DNA
fragmentation and expression of pro-apoptotic proteins p53 and
p21 does not peak until 5–7 days post-infection [17]. This
indicates that that the majority of programmed cell death occurs
long after the peak of virus production. Consistent with these
observations, we show that RV infected cells are in fact, resistant
to apoptosis for at least 48 hours post-infection.
Here, we provide evidence that in addition to functioning in
virus assembly, the RV capsid protein is a potent inhibitor of
apoptosis. With the possible exception of HCV capsid and E2,
structural proteins of RNA viruses have been found to cause
apoptosis rather than prevent cell death (reviewed in [39,44,52]).
As far as we are aware, this is the first example of a structural
protein from an RNA virus that functions to block cell death
pathways through interactions with Bax. Mapping studies suggest
that expression of the virus nonstructural proteins is the cause of
RV-induced cell death [19,20]. Accordingly, counteracting
apoptotic pathways that become activated by expression of these
early proteins may be essential for efficient replication; a theory
that is supported by data from reverse genetic experiments with
the CR5A mutant.
Our data appear to be in disagreement with previously
published data showing that capsid protein expression induces
apoptosis [22]. An important distinction between the previous
study and the present work is that we assayed the ability of capsid
protein to protect against various apoptotic stimuli rather than
assaying whether or not capsid expression induces apoptosis in the
absence of stimuli. In addition, we found that capsid protein blocks
apoptosis in multiple cell lines (including a primary human cell
line) whereas in the afore-mentioned study, capsid protein was
reported to be pro-apoptotic in RK-13 but not other cell lines.
Data in the present study are also consistent with the fact that
stable cell lines that express high levels of RV structural proteins
(including capsid protein) are readily established in a variety of
cells types [19,53,54]. Importantly, the results of the reverse
genetic experiments suggest that the anti-apoptotic function of the
capsid protein is critical for RV replication. Although we cannot
absolutely rule out the possibility that mutations in the R domain
of capsid directly affect its functions in replication and assembly
this seems unlikely. First, the CapCR5A mutant was able to drive
particle assembly and CR5A virions efficiently delivered viral
RNA to host cells. Second, the region of capsid that complements
p150 function in virus replication is in the amino-terminal one
third of the protein [55]. Accordingly, the most logical conclusion
is that the anti-apoptotic role of capsid protein is necessary to
promote survival of the host cell during the long replication cycle.
To our knowledge, this has never been demonstrated before for an
RNA virus but it is tempting to speculate that other slowly
replicating RNA viruses employ similar mechanisms to avoid
killing infected cells.
Although capsid protein may interfere with apoptosis by more
than one mechanism, because the Bax-dependent pathway is a
critical feature of mitochondrial apoptosis in most human cell
types, interfering with the pore-forming ability of this protein is
likely the key anti-apoptotic function of capsid protein. Binding of
capsid protein to Bax induces a major conformational change,
which interestingly, seems to promote activation and oligomeri-
zation of Bax. It is not clear if this phenomenon is related to the
anti-apoptotic activity of capsid or if it is an inconsequential effect
of complex formation with Bax. Figure 14 depicts a model in
Figure 5. Capsid protein forms complexes with Bax. A. Stably transduced A549 cells expressing luciferase (Luc) or capsid protein (Cap) were
treated with staurosporine (ST) for 6 hours. After ST treatment, crude mitochondria were isolated and then crosslinked with BMH prior to analyses by
immunblotting with antibodies to capsid and Bax. The arrowhead in the upper panels denotes an SDS-resistant Bax dimer that is present in all
samples. The asterisk in the lower panels denotes a non-specific protein that cross-reacts with the capsid antibody. A549 cells were infected with RV
and at 42 hours, were treated with ST for 0 to 6 hours. Cell lysates were subjected to immunoprecipitation (IP) with antibodies to capsid, Bax (B) or
Bak (C) followed by SDS-PAGE and immunoblotting (IB).
doi:10.1371/journal.ppat.1001291.g005
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PLoS Pathogens | www.plospathogens.org 10 February 2011 | Volume 7 | Issue 2 | e1001291Figure 6. Capsid expression protects against Bax- but not Bak-induced apoptosis. A549 cells were co-transfected with plasmids encoding
GFP-Bax or GFP-Bak together with plasmids encoding capsid, CapNT, Bcl-XL (not shown) or vector alone. After 24 hours, samples were stained with
TMRM for 30 minutes and then subjected to flow cytometric analyses. Sample FACS plots for GFP-Bax (A) and GFP-Bak (B) transfectants are shown. C.
The levels of relative specific cell death in GFP positive cells were calculated and plotted. Error bars indicate standard deviations calculated from three
independent experiments. *p#0.001, **p#0.01.
doi:10.1371/journal.ppat.1001291.g006
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PLoS Pathogens | www.plospathogens.org 11 February 2011 | Volume 7 | Issue 2 | e1001291Figure 7. Capsid expression prevents Bax-induced release of cytochrome c from mitochondria. A549 cells were co-transfected with
plasmids encoding capsid or vector alone together with GFP-Bax (A) or GFP-Bak (B). After 24 hours, cells were stained with mouse anti-capsid and
rabbit anti-cytochrome c. Primary antibodies were detected with chicken anti-mouse Alexa594 and donkey anti-rabbit Alexa637. Asterisks mark Bax
or Bak expressing cells that have released their mitochondrial stores of cytochrome c into the cytoplasm. In part A, the arrows denote a cell
expressing both capsid and Bax. In this cell, it can be seen that cytochrome c remains associated with mitochondria. In part B, the arrowheads denote
a cell expressing both capsid and Bak. However, in this case, the cell has released its mitochondrial stores of cytochrome c into the cytoplasm. Images
shown are representative of three independent experiments in which at least 100 cells were examined. Scale bar =10 mm.
doi:10.1371/journal.ppat.1001291.g007
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pores. In some critical aspects, the RV capsid protein may function
analogously to the cytomegalovirus accessory protein vMIA, a
putative Bcl-2 homolog that forms mixed oligomers with Bax [56].
However, confirmation of this theory is dependent upon
determining the structure of the RV capsid protein.
Mapping studies localized the anti-apoptotic activity to the
carboxyl-terminal region of capsid protein. The E2 signal peptide,
which is required for membrane association of capsid protein
[57,58], is also essential for targeting to mitochondria but not for
blocking apoptosis. Conversely, while the membrane proximal
arginine-rich (R) motif in capsid is dispensable for targeting to
mitochondria, it is required for protection from intrinsic and
extrinsic apoptotic stimuli (Table 1). The R motif (RSARHP-
WRIR) of RV capsid bears remarkable similarity to the Bax-
binding motif (RRHRFLWQRR) in vMIA [59] which is critical
for blocking Bax- but not Bak-dependent apoptosis [60]. Despite
the apparent similarities between vMIA and RV capsid protein,
one difference worth noting is that the arginine-rich motif in
capsid is not required for binding to Bax.
As mentioned above, it is possible that capsid protein blocks
apoptosis through other mechanisms, at least one of which does
not involve Bax. For example, CapCT, which neither binds to nor
activates Bax, protects cells from staurosporine and Fas-dependent
apoptosis. However, unlike full-length capsid, CapCT does not
protect cells from Bax over-expression. Capsid binds two other
pro-apoptotic proteins p32 and Par-4 [61] and through seques-
tration into non-functional complexes, it is possible that the
functions of these proteins in apoptotic signaling are mitigated.
Although we have no direct evidence to support this theory,
binding to membrane-associated capsid protein may prevent Par-4
from engaging in pro-apoptotic complexes in the nucleus or cell
surface [62,63,64]. Finally, we showed that translocation of the
capsid-binding pro-apoptotic protein p32 into mitochondria is
inhibited by RV infection [12]. Because targeting of p32 to
mitochondria is critical for its function in programmed cell death
pathways [65,66], reducing the levels of mitochondrial p32 would
be expected to reduce apoptosis.
To summarize, we describe a novel mechanism by which a viral
capsid protein potently blocks apoptosis. Our data suggest that this
function of capsid is important for virus replication and it is also
tempting to speculate that establishing and/or maintaining
persistent infections in vivo also requires this activity. RV is known
to persistently infect lymphocytes and capsid-dependent inhibition
of Fas-dependent apoptosis may allow the virus to disseminate
through the body using apoptosis-resistant lymphocytes as
conduits. It will be of interest to examine proteins from other
slowly replicating RNA viruses to determine if capsids or other
proteins double as inhibitors of apoptosis.
Materials and Methods
Reagents
The following reagents were purchased from the respective
suppliers: Protein A and G Sepharose from GE Healthcare Bio-
Sciences Corp (Princeton, NJ); General lab chemicals from Sigma
Chemical Co. (St. Louis, MO); Media and fetal bovine serum
(FBS) for cell culture from Life Technologies-Invitrogen, Inc.
Figure 9. The anti-apoptotic function of capsid protein maps to the carboxyl-terminal region. A549 cells were transiently transfected
with various capsid constructs or Bcl-XL and at 42 hours post-transfection, cells were treated with staurosporine or anti-Fas for 6 hours after which
the numbers of transfectants that were positive for active caspase 3 (double positive) were determined by indirect immunofluorescence. Error bars
indicate standard deviations calculated from three independent experiments. *p#0.0001, **p#0.001.
doi:10.1371/journal.ppat.1001291.g009
Figure 8. The E2 signal peptide is required for targeting of capsid protein to mitochondria. A. Schematic of capsid constructs used for
transfection experiments. RNA=RNA-binding domain; R=Arginine-rich motif; SP=E2 signal peptide. Numbers denote the amino acid residues of
capsid protein. B. A549 cells were transfected with plasmids encoding capsid constructs and were then processed for indirect immunofluorescence
after 40 hours. With the exception of transfectants expressing CapNT, all samples were stained with mouse anti-capsid and rabbit anti-cytochrome c
to label mitochondria. Primary antibodies were detected with chicken anti-mouse Alexa594 and donkey anti-rabbit Alexa488. CapNT was detected
using goat anti-RV serum and chicken anti-goat Alexa594. Nuclei were stained with DAPI. Scale bar =10 mm.
doi:10.1371/journal.ppat.1001291.g008
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the American Type Culture Collection (Manassas, VA.). Hel-18
cells [17] were obtained from Dr. Eva Gonczol, (National Center
for Epidemiology, Budapest, Hungary).
Mammalian cell culture and virus infection
A549 and HEK 293T cells were cultured in Dulbecco’s minimal
essential medium (high glucose) containing 10% FBS, 2 mM
glutamine, 1 mM HEPES, and antibiotics. Vero cells were
cultured in Dulbecco’s minimal essential medium (high glucose)
containing 5% FBS, 2 mM glutamine, 1 mM HEPES, and
antibiotics. RK-13 cells were cultured in minimum essential
medium containing 10% FBS, 2 mM glutamine, 1 mM HEPES,
0.1 mM non-essential amino acids, and antibiotics. Hel-18 cells
were cultured in RPMI-1640 medium containing 10% FBS,
2 mM glutamine, 1 mM HEPES, 0.1 mM non-essential amino
acids, and antibiotics. Cells were incubated at 37uCi na
humidified atmosphere with 5% CO2. RV stocks were diluted
with cell culture media and then added to cells that had been
washed with PBS. Cells were incubated with the virus (1 ml/
35 mm dish) for 4 hours at 35uC after which time the inoculum
was replaced with normal growth media. Infected cultures were
kept at 35uC until experimental analyses.
To investigate the effect of blocking apoptosis on virus
replication, Vero cells were infected with M33 (wild type) or
CR5A strainsofRV(MOI:1)inthe presenceof50 mMpan-caspase
inhibitorZ-VAD-FMK(Promega, Madison,WI)whichwasinitially
made as a 20 mM stock solution in dimethyl sulfoxide (DMSO). Z-
VAD-FMK or control vehicle (DMSO) was added to infected cells
every 24 hrs. Samples were processed at the indicated time points
and virus titers were determined by plaque assay [67].
Plasmid construction and lentivirus production
Plasmids for expression of pCMV5-Capsid, pCMV5-CapCT,
pCMV5-CapDSP and pCMV5-E2E1 have been described previ-
ously [58,67,68]. An expression plasmid encoding amino acid
residues 1–152 of capsid (CapsidNT) was constructed by polymerase
chain reaction (PCR) using a forward primer with a EcoRI site and a
Kozak consensus ribosome-binding site (59-CGGAATTCGCCAC-
CATGGCTTCCACTACCCCCATCACC-399) and areverse prim-
er with a BamHI site and stop codon (59-CGCGCGGATCCC-
TAGGCCTCAGTGGGTGC-39). The restriction sites are
underlined in the primer sequences. The CapDRSP cDNA which
encodes amino acid residues 1–267 of capsid, was constructed by
PCR using the forward EcoRI and Kozak site-containing forward
primer (59-CGGAATTCGCCACCATGGCTTCCACTACCCC-
CATCACC-399) and a reverse primer with a BamHI site and stop
codon (59-CGCGCGGATCCCTACTCGGTGGTGTGAGGG-
39) .T h et e m p l a t ec D N Af o rt h eC a p N Ta n dC a p DRSP PCR
reactions was pCMV5-capsid. The CapC5RA expression plasmid
was prepared by PCR using a forward primer containing an EcoRI
site and a Kozak site (59-TCACGGAATTC-39) and a reverse primer
containing a BamHI site (59-TCAGGATCCCTAGGCGCGC-
GCGGTGC-39). The template DNA was pBRM33-CR5A. The
CapsidNT, CapsidDRSP, and CapsidC5RA cDNAs were resulting
products were sublconed into the EcoRI and BamHI sites of the
mammalian expression vector pCMV5 [69] to produce pCMV5-
CapNT, pCMV5-CapDRSP and pCMV5-CapCR5A respectively.
For establishing capsid and luciferase expressing stable cell lines,
the Lenti-X-tet-On advanced inducible expression system (Clon-
tech Laboratories, La Jolla, CA) was utilized. A cDNA encoding
full-length capsid was amplified by PCR using a forward primer
with a BamHI site and Kozak consensus ribosome binding site (59-
TAGGATCCGCCACCATGGCTTCCACTACCCCCATCACC-
39) and a reverse primer with a EcoRI site (59-GGCCGAATTCC-
TAGGCGCGCGCGGTGC-39) respectively, where the restric-
tion sites are underlined. The DNA used as a template was
pCMV5-capsid. The PCR product was digested with BamHI and
EcoRI, and subcloned into the pLVX-Tight-Puro vector. Lentivi-
rus-production in HEK 293T and transduction of A549 cells were
performed as per the manufacturer’s instructions. At 48 hours
post-transduction, cells were split 1:2 into medium containing
G418 (500 mg/ml) and puromycin (0.5 mg/ml). Surviving cells
were tested for inducible expression of capsid by indirect
immunofluorescence and immunoblot analyses. The resulting
polyclonal stable cell lines A549-Luciferase and A549-Capsid were
maintained in media containing G418 (250 mg/ml) and puromy-
cin (0.25 mg/ml). To induce capsid or luciferase gene expression
doxycycline (1 mg/ml) was added to the culture medium.
Construction of RV strain with mutations in Arginine-rich
domain
Codons for arginine-to-alanine mutations in the C-terminus of
capsid were introduced into the RV M33 infectious clone
(pBRM33) [70] by a two step cloning procedure. A 421 base
pair synthetic fragment (Epoch BioLabs Inc, Sugarland, TX)
containing five arginine-alanine substitutions (R264, 268, 271,
275, 277) was used to replace the analogous region in pCMV5-
24S [68]. The resulting plasmid was named pCMV5-24S-CR5A.
Next, the BsrGI/BamHI fragment from pCMV5-24S CR5A was
used to replace the analogous region (BsrGI/BamHI) in pBRM33
resulting in the infectious clone pBRM33-CR5A.
Quantitative PCR
Total RNA samples were isolated with TRI Reagent
(Ambion) from Vero cells infected with M33 (wild type) or
Table 1. Properties of Capsid mutants.
Construct Mitochondria localization Bax binding Protection against anti-Fas Protection against ST
Capsid Yes Yes Yes Yes
CapNT No No No No
CapCT Yes No Yes Yes
CapDSP No Yes Yes Yes
CapDRSP No No No No
CapCR5A Yes Yes
aND
aND
aND= Not determined.
doi:10.1371/journal.ppat.1001291.t001
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PLoS Pathogens | www.plospathogens.org 15 February 2011 | Volume 7 | Issue 2 | e1001291Figure 10. The arginine-rich motif in capsid protein is not required for targeting to mitochondria or activation of Bax. A. In the
CapC5RA mutant, 5 arginine residues in the R motif were changed to alanines. RNA = RNA binding site; R= arginine-rich motif; SP = E2 signal
peptide. B. A549 cells were transfected with plasmids encoding wild type capsid or CapC5RA. At 40 hours post-transfection, cells were processed for
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instructions. Prior to the RT-PCR reaction, 1 mgo ft o t a lR N A
was treated with 2 U of amplification grade DNase I
(Invitrogen) as per manufacturer’s recommendations. The
DNase I-treated RNA samples were reverse transcribed to
single-stranded cDNA using qScript Flex cDNA synthesis kit
and Oligo (dT)20 primer (Quanta Biosciences, Gaithersburg,
M D )a sp e rm a n u f a c t u r e ’ si n s t r u c t i o n s .
Quantitative PCR reactions were conducted on a MX3005P
thermocycler (Stratagene, La Jolla, CA) using a PerfecCTa SYBR
green supermix low Rox real-time PCR kit (Quanta Biosciences).
Reactions were carried out by triplicate in a total volume of 25 ml
Figure 11. The carboxyl-terminal R motif in capsid protein is required for binding to Bax. A549 cells transiently expressing capsid, CapNT,
CapCT, CapDSP, CapDRSP, CapC5RA or vector alone were subjected to immunoprecipitation (IP) with rabbit anti-Bax under non-denaturing
conditions. Samples were resolved by 10% (A) or 15% (B) SDS-PAGE and analyzed by immunoblotting (IB) with goat anti-RV to detect capsid proteins
or mouse anti-Bax. Arrowheads in the lower panel denote the various capsid constructs. The asterisk indicates IgG light chain.
doi:10.1371/journal.ppat.1001291.g011
indirect immunofluorescence using goat anti-RV, rabbit anti-cytochrome c and a mouse monoclonal antibody specific for activated Bax (6A7). Asterisk
denotes a cell expressing CapC5RA that has loss its mitochondrial stores of cytochrome c. C. Samples were processed as in panel B except that a
mouse monoclonal antibody to Complex II was included (instead of anti-Bax) to show that CapCR5A was targeted to mitochondria. Scale bars
=10mm.
doi:10.1371/journal.ppat.1001291.g010
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PLoS Pathogens | www.plospathogens.org 17 February 2011 | Volume 7 | Issue 2 | e1001291Figure 12. The carboxyl-terminal R motif in capsid protein is required to block apoptosis during RV infection. A. A549 cells were
infected with wild type (WT) or CR5A strains of RV (MOI=1) and 42 hours later, cells were treated with anti-Fas to induce apoptosis. Cells were
processed for indirect immunofluorescence using rabbit anti-caspase 3 and mouse anti-capsid. The average number of double-positive cells for each
experimental condition was determined from three independent experiments and the results were plotted. *p#0.005, **p#0.001. B. Vero cells were
infected with WT or CR5A strains of RV (MOI=1). At the indicated times, cell lysates (60 mg) were subjected to immunoblot analyses using antibodies
to p150, capsid, E1 and GAPDH (loading control). C. Cell culture supernatants from infected Vero cells were centrifuged at 100,0006g and the pellets
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primer. Primers used to amplify RV nucleotides 5520–5706 from
the RV p90 non-structural protein coding region of the RV
genome were as follow: RV-F (59-AGGTCATGTCTCCG-
CATTTC-39) and RV-R (59-GTCCCGAGTAGCAAGGG-
TCT-39). The amplification cycles for p90 samples consisted of
an initial denaturating cycle at 95uC for 3 min, followed by 40
cycles of 15 s at 95uC, 30 s at 58uC, and 20 s at 72uC.
Fluorescence was quantified during the 58uC annealing step,
and the product formation was confirmed by melting curve
analysis (57uCt o9 5 uC). As an internal control, levels of the house
keeping gene product cyclophilin A determined. Amplification was
performed using the following primers, CYP-F (59- TCCAAA-
GACAGCAGAAAACTTTCG-39) and CYP-R (59-TCTTC-
TTGCTGGTCTTGCCATTCC-39). The amplification cycles
for Cyclophilin A consisted of an initial denaturating cycle at
95uC for 3 min, followed by 40 cycles of 15 s at 95uC, 20 s at
60uC, and 40 s at 72uC. Fluorescence was quantified during the
60uC annealing step, and the product formation was confirmed by
melting curve analysis (57uCt o9 5 uC).
Quantification of the samples was performed using the two
standard curves method [71], and the relative amount of RV
genomic RNA was normalized to the relative amount of
Cyclophilin A mRNA. Three independent PCR analyses were
performed for each sample.
Immunoprecipitation and immunoblotting
A549 cells (1610
5) in 35 mm culture dishes were infected with
the M33 strain of RV (MOI=2) and then incubated for 48 hours
at 35uC prior to lysis. Alternatively, A549 cells were transiently
transfected with pCMV5-capsid, pCMV5-CapNT, pCMV5-
CapCT, pCMV5-CapDSP, pCMV5-CapDRSP or pCMV5-Cap-
CR5A using Lipofectamine 2000 (Invitrogen). Cells were lysed in
1% (wt/vol) CHAPS, 150 mM NaCl, 50 mM Tris, pH 8.0
containing Complete EDTA-free protease inhibitors (Roche) or
1% NP-40, 150 mM NaCl, 2 mM EDTA, 50 mM Tris, pH 7.4
containing protease inhibitors. Cell lysates were clarified by
centrifugation at 10,0006g for 10 minutes at 4uC. Immunopre-
cipitation was performed with clarified lysates and 1 mg/ml of
mouse monoclonal anti-Bax6A7 (Sigma), or 1:1000 of rabbit
polyclonal anti-capsid serum (7W7), or 2 mg/ml of rabbit anti-Bak
(Millipore) antibodies overnight at 4uC with rotation. Fifteen
microliters of protein A or protein G sepharose (50% suspension)
were added and then samples were rotated for 1 hour at 4uC
before washing; twice with lysis buffer and once with PBS. Proteins
were eluted from the beads by boiling in protein gel sample buffer,
separated by SDS-PAGE, and then transferred to polyvinylidene
fluoride (PVDF) membranes (Immobilon-P Millipore, Bedford,
MA). Membranes were incubated for 1 hour at room temperature
with the following antibodies and dilutions: 1:1000 rabbit anti-RV
capsid (7W7) [61],1:1000 mouse anti-capsid (H15C22), 1:1000
goat anti-RV (Meridian Life Science Inc, Saco, Maine), 1:1000
rabbit anti-Bak (Cell Signaling), 1:1000 rabbit anti-Bax (Abcam) or
1:5000 mouse anti-Bax (YTH-2D2, Trevigen Inc, Gaithersburg,
MD). To detect E1 glycoprotein by immunoblotting, it was
necessary to perform SDS-PAGE under non-reducing conditions.
E1 was detected using a 1:1000 dilution of a mouse monoclonal
antibody (H2C213) obtained from Abbott Labs (Abbott Park, IL).
After three washes with Tris-Buffered-Saline-Tween (TBS-T), the
membranes were incubated with either goat anti-rabbit, goat anti-
mouse or rabbit anti-goat horseradish peroxidase-conjugated IgG
(Bio-Rad Hercules, CA) for 1 hour. Membranes were washed four
times with TBS-T and immunoreactive proteins were detected
using Supersignal West Pico chemiluminescent substrate (Pierce
Biotechnology, Rockford, IL) followed by exposure to X-ray film
(Fuji Photo Film Co, LTD, Tokyo, Japan).
PARP cleavage assay
A549-Capsid or A549-Luciferase cells were cultured in the
presence of doxycycline and after 36 hours, anti-human Fas
activating clone CH11 antibody (0.12 mg/ml) (Millipore, Teme-
cula, CA) and cycloheximide (10 mg/ml) were added to the
cultures for 6 hours. Cells were then lysed in 1% NP-40 buffer
containing a cocktail of protease inhibitors. The lysates were
centrifugated at 10,0006 g for 10 min at 4uC, and protein
concentrations were determined by BCA protein assay (Pierce
Biotechnology, Rockford, IL) using bovine serum albumin as a
standard. Equivalent amounts of protein (60 mg) from each lysate
were resolved in 8% SDS-PAGE and transferred to PVDF
membranes followed by immunoblotting with mouse monoclonal
anti-cleaved PARP (Asp214) clone 19F4 antibody (Cell Signaling).
Indirect immunofluorescence microscopy
A549 and Vero cells cultured on glass coverslips were infected
with RV (MOI=1) or transiently transfected with pCMV5-capsid
or pCMV5-CapNT or pCMV5-CapCT or pCMV5-CapDSP or
pCMV5-CapDRSP or pCMV5-E2E1 or pcDNA3.1-Bcl-XL, and
peGFP-Bax or peGFP-Bax (Gift of Dr. Michele Barry, University
of Alberta) using Lipofectamine 2000 (Invitrogen). After 24 or
48 hours post-infection or post-transfection as indicated, cells were
fixed in 4% paraformaldehyde for 20 min, followed by quenching
with PBS containing 50 mM ammonium chloride. Cell mem-
branes were permeabilized with PBS containing 0.2% Triton-X-
100 for 5 min before incubation with primary and secondary
antibodies. All the washes were done in PBS containing 0.1 mM
CaCl2 and 1 mM MgCl2.
RV proteins were detected with rabbit anti-capsid (7W7), mouse
anti-capsid (H15C22), mouse-anti E1 (H2C213), goat anti-RV, or
human anti-RV (GB) which has been described previously.
Mitochondria were detected using rabbit anti-cytochrome c (from
Dr. L. Berthiaume, University of Alberta) or with a mouse anti-
complex II monoclonal antibody (Mitosciences, Eugene, OR).
Activated isoforms of Bax and capsase 3 were detected with a Bax-
specific mouse monoclonal antibody 6A7 (Abcam) or caspase 3-
specific rabbit monoclonal antibody (BD Pharmingen) respectively.
Primary antibodies were detected with Alexa Fluor 594 chicken
anti-mouse, Alexa Fluor 488 donkey anti-rabbit, Alexa Fluor 488
Table 2. Relative genomic RNA levels in infected Vero cells.
Hours post-infection
RV strain 62 4 4 8 7 2
WT 1 623.26116.8 336.56138.3 818.8628.5
CR5A 1.760.1 14.764.5 94.6657.5 245.4618.6
doi:10.1371/journal.ppat.1001291.t002
were subjected to immunoblot analyses using antibodies to capsid. D. Relative levels of genomic viral RNA (gRNA) in the infected Vero cells were
determined by qRT-PCR at the indicated time periods. E. RK13 cells were infected with wild type WT or CR5A strains of RV and plaque assays were
performed. The CR5A-derived plaques are much larger and have a spotty appearance.
doi:10.1371/journal.ppat.1001291.g012
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Alexa 594 goat anti-rabbit(Molecular Probes, Invitrogen, Carlsbad,
CA). Coverslips were mounted onto microscope slides using
ProLong Gold antifade reagent with 4’-6-Diamidino-2-phenylin-
dole (Molecular probes, Invitrogen). Samples were then examined
using Zeiss 510 confocal microscope or a Zeiss Axioskop2
microscope equipped with a CoolSNAP HQ digital camera
(Photometrics).
Isolation of mitochondria and Bax cross-linking
A549-Cap or A549-Luciferase cells were cultured for 36 hours in
the presence of doxycycline, followed by incubation with 1 mM
staurosporine (Sigma-Aldrich) or anti-Fas antibody (0.12 mg/ml)
and cycloheximide (10 mg/ml) for 6 hours. Cells were then
homogenized in ice-cold mitochondria isolation buffer containing
200 mM mannitol, 70 mM sucrose, 10 mM Hepes, and 1 mM
EGTA (pH: 7.5) using a dounce homogenizer with a loose fitting
pestle. Unbroken cells and nuclei were pelleted by centrifugation at
5006g for 10 min at 4uC. The supernatants were then centrifuged
at 10,0006 g for 20 min at 4uC to obtain crude mitochondrial
pellets that were cross-linked with 10 mM bis(maleimido)hexane
(BMH; Thermo Scientific) for 30 min at room temperature.
Samples then were separated on 4–12% polyacrylamide gels and
then processed for immunobloting with rabbit polyclonal antibodies
to Bax antibody (Abcam, Cambridge, MA) and capsid (7W7).
Measurement of mitochondrial membrane potential by
flow cytometry
Expression of capsid or luciferase in A549-cap or A549-luc cells
respectively was induced with doxycycline for 36 hours, followed by
incubation with staurosporine (1 mM)or anti-Fas antibody (0.12 mg/
ml) to induce apoptosis. Cells then were stained with 0.2 mM
Tetramethylrhodamine methyl ester (TMRM) (Invitrogen, Molec-
ular probes) for 30 min at 37uC before analyses by flow cytometry
(FACScan, Becton Dickinson). For each sample, 10,000 events were
acquired. Data were analyzed using CellQuest software. The
Figure 13. Vero cells that were infected with the CR5A mutant or wild type RV were treated with DMSO (-) or Z-VAD-FMK (50 mM)
every day for up to 3 days. A. Cell lysates and culture supernatants were harvested at indicated time periods. Equal amounts of cell lysates (60 mg)
were subjected to immunoblot analyses with antibodies to viral (p150 and capsid) and cellular proteins (GAPDH). At each time point, the relative
signals of the p150/GAPDH and capsid/GAPDH in DMSO-treated cells were normalized to 1.0. Relative ratios of Z-VAD-FMK to DMSO samples were
then determined. In some cases (ND), it was not possible to determine the relative ratios due to low signal intensity. B. Media from infected cells were
serially diluted 10-fold before addition to RK-13 monolayers for plaque assays. Based on the clearing of cell monolayers, it can be seen that
supernatants from CR5A infected Z-VAD-FMK-treated Vero cells contain more infectious virus.
doi:10.1371/journal.ppat.1001291.g013
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negative cells divided by the total number of cells, and standard
deviations were determined from three independent experiments.
For Bax or Bak killing assays, A549 or Hel-18 cells were
transfected with peGFP-Bax or peGFP-Bak together with
pCMV5, pCMV5-CapNT, or pCMV5-capsid using Lipofecta-
mine 2000 or Lipofectamine LTX respectively (Invitrogen). After
24 hours, cells were stained with 0.2 mM TMRM for 30 min at
37uC prior to analyses by two-color flow cytometry. TMRM
fluorescence was detected through the FL-2 channel equipped
with a 585-nm filter and eGFP fluorescence was measured using
the FL-1 channel equipped with a 489-nm filter. Data were
acquired on 10,000 eGFP-positive cells per sample, and analysis
was performed using CellQuest software. The relative specific cell
death was calculated as the number of eGFP-positive TMRM-
negative cells divided by the total number of eGFP positive cells.
Standard deviations were generated from three independent
experiments.
Rubella virus-like particle assay
Vero cells (1610
5/35 mm dish) were transiently transfected
with pCMV5-capsid or pCMV5-CapCR5A and pCMV5-E2E1
using Lipofectamine 2000. Assembly and secretion of RV-like
particles was assayed after 48 hours of transfection as described
elsewhere [58].
Statistical analyses
Data from FACS and indirect immunofluorescence-based
apoptosis assays were subjected to statistical analyses (student’s t
test or one-way analysis of variance (One-way ANOVA)) using
Predictive Analytics Software (version 17.0.3) (SPSS Inc, Chicago,
Il).
Supporting Information
Figure S1 Vero cells that have been infected with RV or that
transiently express capsid protein are resistant to apoptosis. A.
Vero cells were infected with RV (MOI = 1) or transiently
transfected with plasmids encoding capsid, eGFP, E2 and E1 or
Bcl-XL (B). After 40 hours, cells were treated with staurosporine
(ST) for 6 hours. Samples were then processed for indirect
immunofluorescence using rabbit anti-caspase 3 and mouse anti-
capsid. Primary antibodies were detected with donkey anti-rabbit
Alexa488 and chicken anti-mouse Alexa594. Nuclei were counter
Figure 14. Model for how capsid blocks Bax-dependent apoptosis. Apoptotic stimuli can induce a conformational change in Bax, which is
followed by stable membrane association and oligomerization. The Bax oligomers serve as pores that faciliate efflux of cytochrome c from the
mitochondria to the cytoplasm where it initiates downstream apoptotic signaling through the apoptosome. The RV capsid protein binds to Bax
before or after it is translocated to mitochondria. Interaction with capsid is followed a conformational change in Bax and subsequent hetero-oligomer
formation. However, the Bax-capsid oligomers do not allow efflux of cytochrome c from the mitochondria and apoptosis is blocked.
doi:10.1371/journal.ppat.1001291.g014
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Bcl-XL-expressing cells that are caspase 3 negative. Images shown
are representative of at least three independent experiments in
which at least 100 cells were examined. Scale bar = 10 mm.
Found at: doi:10.1371/journal.ppat.1001291.s001 (1.56 MB TIF)
Figure S2 Expression of capsid protein in RK-13 cells blocks
apoptosis. RK-13 cells were transiently transfected with plasmids
encoding eGFP, E2 and E1, capsid or Bcl-XL. A. At 42 and 66
hours post-transfection, cells were treated with staurosporine (ST)
for 6 hours after which the numbers of transfectants that were
positive for active caspase 3 (double positive) were determined by
indirect immunofluorescence. * Differences are statistically
significant according to oneway ANOVA with 95% confidence
interval. B. At 42 hours post-transfection, cells were treated with
anti-Fas for 6 hours after which the numbers of transfectants that
were positive for active caspase 3 (double positive) were
determined by indirect immunofluorescence. A minimum of 100
transfectants were analyzed per sample. Error bars indicate
standard deviations calculated from three independent experi-
ments. p = # 0.001
Found at: doi:10.1371/journal.ppat.1001291.s002 (0.26 MB TIF)
Figure S3 Expression of capsid protein in stably transduced
A549 cells protects against staurosporine- and Fas-induced
activation of capsase 3. A. A549 cells were stably transduced with
lentiviruses encoding RV capsid or luciferase (control). Expression
of capsid and luciferease was induced with doxycycline for 48
hours after which cells were treated with staurosporine (ST) or
anti-Fas for 6 hours to induce apoptosis. Samples were then
processed for indirect immunofluorescence using rabbit anti-
caspase 3 and mouse anti-capsid. Primary antibodies were
detected with donkey anti-rabbit Alexa488 and chicken anti-
mouse Alexa594. Nuclei were counter stained with DAPI. Scale
bar = 10 mm. B. The percentages of active capsase 3-positive cells
were determined from three independent experiments in which at
least 100 cells for each experiment were scored. Error bars indicate
standard deviations calculated from three independent experi-
ments. *p# 0.01, **p# 0.01
Found at: doi:10.1371/journal.ppat.1001291.s003 (0.89 MB TIF)
Figure S4 Expression of capsid protein protects primary human
cells from Bax-induced apoptosis. HEL-18 cells cells were co-
transfected with plasmids encoding GFP-Bax together with
plasmids encoding capsid, CapNT, or vector alone. After 24
hours, samples were stained with TMRM for 30 minutes and then
subjected to flow cytometric analyses. A. Sample FACS plots for
GFP-Bax transfectants are shown. B) The levels of relative specific
cell death in 5,000 GFP positive cells were calculated and plotted.
Error bars indicate standard deviations calculated from three
independent experiments.
Found at: doi:10.1371/journal.ppat.1001291.s004 (0.40 MB TIF)
Figure S5 The CapCR5A mutant is fully functional for
assembly of rubella virus like-particles (RLP). Vero cells were
transfected with plasmids encoding vector; WT capsid alone
(Capsid); or a plasmid encoding glycoproteins E2 and E1 with
Capsid or CapCR5A. After 48 hours, RLPs recovered from the
pre-cleared media by centrifugation at 100,000 x g were detected
by immunoblotting with a rabbit polyclonal antibody.
Found at: doi:10.1371/journal.ppat.1001291.s005 (0.18 MB TIF)
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